PluriPLUR -8.21%29 Receivables Turnover is 1.25 as of Mar. 2026. GuruFocus rates PLUR with a GF Score™ of 29/100 and a GF Value™ of $6.51 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 839 Biotechnology companies, Pluri ranks worse than 56.14% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Pluri's Revenue for the
three
months ended in Mar. 2026 was $0.17 Mil. Pluri's average Accounts Receivable for the
three
months ended in Mar. 2026 was $0.13 Mil.
Hence, Pluri's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.25.
Pluri (NAS:PLUR) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Pluri Receivables Turnover Related Terms
Pluri Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Pluri's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PLUR vs MRKR, VYNE, LGVN: Receivables Turnover Comparison
For the Biotechnology subindustry, Pluri's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pluri Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pluri's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Pluri's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pluri (PLUR) has a Receivables Turnover of 1.25 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Pluri and its competitors. According to the industry distribution chart, Pluri ranks #471 out of 839 companies in the Biotechnology industry, placing it in the top 56.1%.
Is Pluri's Receivables Turnover too high?
Pluri's current Receivables Turnover is 1.25. The Biotechnology industry median Receivables Turnover is 5.29. Pluri's value of 1.25 is 76.4% below this industry median. Based on the distribution chart, Pluri ranks #471 out of 839 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Pluri has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pluri's Receivables Turnover compare to MRKR and VYNE?
According to the Biotechnology industry distribution chart, Pluri ranks #471 out of 839 companies for Receivables Turnover. This places Pluri in the lower half of its industry. The industry median Receivables Turnover is 5.29. Pluri's value of 1.25 is 76.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pluri's current Receivables Turnover of 1.25 is 76.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Pluri and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pluri's current Receivables Turnover is 1.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pluri stock overvalued right now?
Based on GuruFocus' analysis, Pluri (PLUR) is currently considered Possible Value Trap. The stock's GF Value™ is $6.51, compared to a current price of $1.90 — trading 70.8% below its estimated fair value. The current Receivables Turnover is 1.25 and 76.4% below the Biotechnology industry median of 5.29. Pluri's overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Pluri (PLUR), the current Receivables Turnover is 1.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pluri (PLUR) Overvalued in 2026?
Based on GuruFocus' analysis, Pluri stock appears to be undervalued.
The current stock price of $1.90 is trading 70.8% below its estimated GF Value™ of $6.51.
GuruFocus considers Pluri to be Possible Value Trap.
Key valuation signals for PLUR:
Receivables Turnover: 1.25
GF Value™: $6.51 vs. price of $1.90 (70.8% below fair value)
Industry Position: 76.4% below the Biotechnology median (#471 of 839)
No single metric tells the full story. See the PLUR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
29GF Score
Get the complete analysis for PLUR
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLUR has been successfully added to your 
